People · Operator
Named in public records as an officer, director or promoter · active 2009–2023 · Other Health Care, Biotech / Pharma, Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Calypso Medical Technologies Inc | — | Other Health Care | Series C | $69.5M | $171.5M | 2009 |
| BlueSphere Bio, Inc. | — | Biotech / Pharma | Series C | $55.6M | $1.5B | 2018 |
| IDev Technologies Inc | — | Other Health Care | Series B | $44.2M | $18.4M | 2009 |
| Nupathe Inc. | — | Pharmaceuticals | Series B | $39.2M | $952.1M | 2010 |
| Novasenta Inc. | — | Biotechnology | Series A | $25.0M | $100.5M | 2022 |
| Generian Pharmaceuticals, Inc. | — | Biotech / Pharma | Series A | $13.0M | $435.2M | 2019 |
| Inspired Technologies Inc | — | Biotechnology | Series A | $7.1M | $56.9M | 2009 |
Jeanne Cunicelli at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jeanne Cunicelli on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Matthias Kleinz | 2 | 2 |
| DAVID MOORE | 1 | 13 |
| Ned Renzi | 1 | 8 |
| David Gill | 1 | 8 |
| Alan Levy | 1 | 7 |
| Michael Sweeney | 1 | 7 |
| John Freund | 1 | 7 |
| Ross Jaffe | 1 | 7 |
| Richard S. Kollender | 1 | 7 |
| James A. Datin | 1 | 6 |
| Jay Schmelter | 1 | 6 |
| Gary J. Kurtzman | 1 | 6 |
| Craig Walker | 1 | 5 |
| Michael Stubler | 1 | 5 |
| Alan Frazier | 1 | 5 |
| Rick Anderson | 1 | 4 |
| William Burke | 1 | 4 |
| Stephen Arnold | 1 | 4 |
| Michael F. Cola | 1 | 3 |
| Christopher M Owens | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.